Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
LONDON - Fever-Tree, a leading supplier of premium carbonated mixers, has completed the issuance of equity to Molson Coors (NYSE:TAP) Beverage Company as part of their strategic partnership established on January 30, 2025. The transaction involved the issuance of 10,856,628 ordinary shares at a price of 654.2 pence per share, resulting in Molson Coors holding an 8.5% stake in the company.
The newly issued shares were admitted for trading on the AIM market of the London Stock Exchange (LON:LSEG) at 8:00 a.m. today, with each share ranking equally with the existing ordinary shares. Following the admission, Fever-Tree’s total issued share capital consists of 127,615,093 ordinary shares, all with voting rights, as the company does not hold any shares in treasury.
Shareholders can use the total number of ordinary shares as the denominator for calculations required under the Financial Conduct Authority’s Disclosure and Transparency Rules to determine their notification obligations regarding changes in share capital interests.
Fever-Tree has established itself as the world’s top supplier of premium mixers by retail sales value, catering to the growing demand for high-quality mixers to accompany premium spirits. The brand, which started in 2005 in the UK, distributes to over 90 countries and serves both the on-trade market—hotels, restaurants, bars, and cafes—as well as selected retail outlets in the off-trade sector.
This share issuance marks a significant development in the relationship between Fever-Tree and Molson Coors, expanding their strategic partnership and potentially signaling future collaborative efforts between the two companies.
The information for this article is based on a press release statement from Fever-Tree, and it does not constitute an offer for sale of securities in the United States or any jurisdiction where such an offer would be unlawful. The securities discussed have not been registered under the US Securities Act of 1933 and are not intended to be offered or sold in the United States absent registration or an exemption from registration under the Securities Act.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.